Akèy › Kansè tete negatif triple › Washington
Etid klinik pou Kansè tete negatif triple nan Washington
20 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
- Cancer Care Northwest ( Site 0003), Spokane
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Northwest Medical Specialties, PLLC ( Site 0093), Tacoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Fred Hutchinson Cancer Center ( Site 0042), Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Providence Regional Cancer System, Lacey
- MultiCare Regional Cancer Center - Tacoma, Puyallup
- Northwest Medical Specialties, PLLC, Puyallup
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Northwest, Spokane Valley
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178SMP-3124LP in Adults With Advanced Solid Tumors
- University of Washington, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06526819A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07078604Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Swedish Cancer Institute, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- University Of Washington, Seattle
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Summit Cancer Center, Spokane
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
- Summit Cancer Centers, Spokane
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Medical Oncology Associates, Spokane
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07503808A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Fred Hutch Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT06682793A Study of NX-1607 in Adults With Advanced Malignancies
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Cancer Care Northwest, Spokane
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Jan 7, 2025 · NCT06230185Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.